rewirebio.iobenchmarks
Source

An Evaluation of DMR-Informed Fine-Tuning of Tissue Array-Pretrained CpGPT for Gastrointestinal Cancer Classification Using cfDNA Targeted Methylation

medRxiv version 1, posted 2026-07-29 · Preprint

DOI: 10.64898/2026.07.26.26358979

Two authors (University of Southern California; MicroTrace BioAI, Inc.) who did not develop CpGPT. They fine-tuned the published CpGPT Cancer-100M checkpoint and built the classical baselines themselves. Not peer reviewed.

What this source contributed

Records in this release that cite this source. A record can cite several sources.

Results

Values as the source printed them. Compare results only under compatible protocols, datasets and metrics.

Model or configurationMetricValueDatasetEvaluation
CpGPT Cancer-100M fine-tuned on 20,499 DMR-informed CpGsAUPRC (GI cancer vs non-cancer, held-out test partition, mean over three split-runs)0.9960 unitlessEpiPanGI Dx plasma cfDNA targeted bisulfite methylation (GSE149438, 300 samples)CpGPT on GSE149438 DMR-informed split-runs (Xu and Feng 2026)
CpGPT Cancer-100M fine-tuned on 20,499 DMR-informed CpGsAUROC (GI cancer vs non-cancer, held-out test partition, mean over three split-runs)0.9904 unitlessEpiPanGI Dx plasma cfDNA targeted bisulfite methylation (GSE149438, 300 samples)CpGPT on GSE149438 DMR-informed split-runs (Xu and Feng 2026)
CpGPT Cancer-100M fine-tuned on 20,499 DMR-informed CpGsAUROC (GI cancer vs non-cancer, validation partition, mean over three split-runs)0.9487 unitlessEpiPanGI Dx plasma cfDNA targeted bisulfite methylation (GSE149438, 300 samples)CpGPT on GSE149438 DMR-informed split-runs (Xu and Feng 2026)
Elastic Net on 20,499 DMR-informed CpGs (caret)AUPRC (GI cancer vs non-cancer, held-out test partition, mean over three split-runs)0.9805 unitlessEpiPanGI Dx plasma cfDNA targeted bisulfite methylation (GSE149438, 300 samples)Elastic Net on GSE149438 DMR-informed split-runs (Xu and Feng 2026)
Elastic Net on 20,499 DMR-informed CpGs (caret)AUROC (GI cancer vs non-cancer, held-out test partition, mean over three split-runs)0.9420 unitlessEpiPanGI Dx plasma cfDNA targeted bisulfite methylation (GSE149438, 300 samples)Elastic Net on GSE149438 DMR-informed split-runs (Xu and Feng 2026)
Elastic Net on 20,499 DMR-informed CpGs (caret)AUROC (GI cancer vs non-cancer, validation partition, mean over three split-runs)0.9300 unitlessEpiPanGI Dx plasma cfDNA targeted bisulfite methylation (GSE149438, 300 samples)Elastic Net on GSE149438 DMR-informed split-runs (Xu and Feng 2026)
GBM on 20,499 DMR-informed CpGs (caret)AUPRC (GI cancer vs non-cancer, held-out test partition, mean over three split-runs)0.9550 unitlessEpiPanGI Dx plasma cfDNA targeted bisulfite methylation (GSE149438, 300 samples)GBM on GSE149438 DMR-informed split-runs (Xu and Feng 2026)
GBM on 20,499 DMR-informed CpGs (caret)AUROC (GI cancer vs non-cancer, held-out test partition, mean over three split-runs)0.8460 unitlessEpiPanGI Dx plasma cfDNA targeted bisulfite methylation (GSE149438, 300 samples)GBM on GSE149438 DMR-informed split-runs (Xu and Feng 2026)
GBM on 20,499 DMR-informed CpGs (caret)AUROC (GI cancer vs non-cancer, validation partition, mean over three split-runs)0.8767 unitlessEpiPanGI Dx plasma cfDNA targeted bisulfite methylation (GSE149438, 300 samples)GBM on GSE149438 DMR-informed split-runs (Xu and Feng 2026)
Random Forest on 20,499 DMR-informed CpGs (caret)AUPRC (GI cancer vs non-cancer, held-out test partition, mean over three split-runs)0.9475 unitlessEpiPanGI Dx plasma cfDNA targeted bisulfite methylation (GSE149438, 300 samples)Random Forest on GSE149438 DMR-informed split-runs (Xu and Feng 2026)
Random Forest on 20,499 DMR-informed CpGs (caret)AUROC (GI cancer vs non-cancer, held-out test partition, mean over three split-runs)0.8408 unitlessEpiPanGI Dx plasma cfDNA targeted bisulfite methylation (GSE149438, 300 samples)Random Forest on GSE149438 DMR-informed split-runs (Xu and Feng 2026)
Random Forest on 20,499 DMR-informed CpGs (caret)AUROC (GI cancer vs non-cancer, validation partition, mean over three split-runs)0.7933 unitlessEpiPanGI Dx plasma cfDNA targeted bisulfite methylation (GSE149438, 300 samples)Random Forest on GSE149438 DMR-informed split-runs (Xu and Feng 2026)
SVM radial on 20,499 DMR-informed CpGs (caret)AUPRC (GI cancer vs non-cancer, held-out test partition, mean over three split-runs)0.9827 unitlessEpiPanGI Dx plasma cfDNA targeted bisulfite methylation (GSE149438, 300 samples)SVM radial on GSE149438 DMR-informed split-runs (Xu and Feng 2026)
SVM radial on 20,499 DMR-informed CpGs (caret)AUROC (GI cancer vs non-cancer, held-out test partition, mean over three split-runs)0.9573 unitlessEpiPanGI Dx plasma cfDNA targeted bisulfite methylation (GSE149438, 300 samples)SVM radial on GSE149438 DMR-informed split-runs (Xu and Feng 2026)
SVM radial on 20,499 DMR-informed CpGs (caret)AUROC (GI cancer vs non-cancer, validation partition, mean over three split-runs)0.9367 unitlessEpiPanGI Dx plasma cfDNA targeted bisulfite methylation (GSE149438, 300 samples)SVM radial on GSE149438 DMR-informed split-runs (Xu and Feng 2026)

Claims

Statements this source supports, each with where in the source it was checked.

  • Evidence summary: plasma ctDNA methylation detection workflows: Summary Six bounded sources compare cfDNA methylation methods. None is a prospective screening study and none measures clinical benefit. Jamshidi et al. 2022 (Cancer Cell), by the GRAIL developers, compared prototype cfDNA classifiers on the same CCGA substudy 1 participants at a 98% specificity threshold set post hoc within each set. On the validation set of 464 cancers and 362 non-cancers, analysed double-blinded, the whole-genome bisulfite methylation classifier detected 34% of cancers (95% CI 30% to 39%; 158 of 464), against 33% for variants with white-blood-cell correction, 30% for copy number with that correction, 27% for copy number, 16% for uncorrected variants and 2.6% for clinical risk factors alone; only the gap to the corrected variant classifier was not marked as significant. Among 127 validation cancers detected by all three representative classifiers, a methylation origin classifier developed after unblinding assigned the correct tissue for 75% (95 of 127), against 41% for copy number and 35% for corrected variants, with 'other' counted as correct for six cancer types. These are case-control results from the assay developer, not screening performance. Sun et al. 2024 (Genome Biology), an independent benchmark whose authors did not develop the tools, deconvolved real plasma with five methods and reported the ROC-AUC of a random forest trained on the estimated cell-type fractions; the paper does not state how the random forest was validated, so the AUCs may be in-sample. For 24 liver cancer patients and 32 healthy individuals (WGBS), AUCs were 0.96 (CelFEER), 0.93 (CelFiE), 0.91 (MethAtlas), 0.77 (cfNOMe) and 0.72 (UXM). On cfMethyl-Seq plasma (30 to 67 patients per cancer type, each against the same 193 healthy individuals), AUCs ranged from 0.72 (UXM, lung squamous cell carcinoma) to 0.93 (CelFiE, gastric cancer), and no method was highest for every cancer type. Giuili et al. 2025, a bioRxiv preprint not yet peer reviewed, ran ten reference-based tools inside the authors' DecoNFlow pipeline on in silico mixtures of tumour tissue or cell-line reads in healthy plasma reads. CelFiE had the lowest overall median tumour-fraction limit of detection in each dataset: 0.0070 (WGBS-TT), 0.0100 (RRBS-TT) and 0.0010 (RRBS-CL). CIBERSORT and EpiDISH had overall medians of 0.1000 to 0.2500 on WGBS-TT and RRBS-TT. For five tools the RRBS-CL values disagree between the supplementary table and Figure 4A and are not shown. Nguyen et al. 2023 (eLife), by the developers of the SPOT-MAS assay at Gene Solutions, compared three tissue-of-origin classifiers on combined methylation, fragment-length, copy-number and end-motif features from cancer patients only. In the validation cohort of 239 patients, overall accuracy was 0.53 (random forest), 0.69 (deep neural network) and 0.69 (graph convolutional network); the graph network was trained with the validation samples in its graph. Zeng et al. 2026 (Nature Cancer), by the cfMeDIP-seq developers, compared a cfMeDIP-seq methylation classifier with fragmentomic features of the same reads and their combinations, reporting means over 10 fold models. In cross-validation on 356 cancers and 64 healthy donors, methylation alone reached AUC 0.986 and detected 0.949 of cancers at 99% specificity; on an independent validation set its sensitivity at 99% specificity was 0.633, against 0.766 for methylation combined with fragment ratios. These sensitivities are read on few healthy controls (six or seven per cross-validation fold and 17 in the validation set), so 99% specificity there allows no false positive among them, and Li-Fraumeni syndrome carriers without current cancer count as cancers in the validation sensitivities. The Source Data give the methylation-only validation AUC as 0.694 and the text as 0.674, so that value is not shown. Xu and Feng 2026, a medRxiv preprint not yet peer reviewed, by authors who did not develop CpGPT, fine-tuned the CpGPT methylation foundation model on public targeted bisulfite cfDNA data from 254 gastrointestinal cancers and 46 non-cancer controls and built four classical classifiers themselves. On three train/validation/test splits with test partitions of about 30 samples, mean test AUROC was 0.9904 for CpGPT against 0.9573 (SVM), 0.9420 (elastic net), 0.8460 (gradient boosting) and 0.8408 (random forest); the candidate CpGs were selected using all 300 samples, including the test partitions. Neither study reports performance in a screening population. Tissue-of-origin evidence here comes from two developer studies, one methylation-only classifier scored on already detected cancers and one multimodal workflow, and neither classifies people without cancer. (ctdnameth-20261009-source-sun2024-additional-file-1: Table S7 I4:M4, M8, J9; ctdnameth-20261009-source-sun2024: Methods P30; ctdnameth-20261009-source-giuili2025-supp-table-3: sheet B B3:D4, B7:C7; ctdnameth-20261009-source-nguyen2023-supp-file-1: Table S9 B19:E19; ctdnajam-20261010-source-jamshidi2022: Table 3 validation column and Results, cancer signal origin prediction; ctdnalit-20261011-zeng2026-source-article: Results P28-P33; ctdnalit-20261011-zeng2026-source-source-data-fig4: sheets Fig.4a-Fig.4d; ctdnalit-20261011-cpgpt2026-source-preprint: Table 3; Methods; Results)
  • Relevance of ctdnalit-20261011-cpgpt2026-protocol-dmr-informed-split-runs to "Which measured methylation workflow detects tumour-derived plasma DNA and, where separately supported, identifies tissue of origin?": Assessed by Xu and Feng 2026: GI cancer vs non-cancer on GSE149438, three train-validation-test split-runs, DMR-informed CpG features (ctdnalit-20261011-cpgpt2026-source-preprint: Table 3; Methods; Results)

Models, benchmarks and other records

Methods (2)

Configurations (5)

Protocols (1)

Datasets (1)

Evaluations (5)

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

22 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance
Archive note
Not archived: no reuse licence. The artifact_sha256 pins the bytes that were read.
Source metadata
An Evaluation of DMR-Informed Fine-Tuning of Tissue Array-Pretrained CpGPT for Gastrointestinal Cancer Classification Using cfDNA Targeted Methylation

Original source ↗

No field-specific location recorded

Version: medRxiv version 1, posted 2026-07-29
Retrieved: 2026-10-11T21:49:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.archive_note

Source artifact SHA-256: 369746bfe0117866d294e01f49c6ffbfc2d177e347872030d6233e2e7366961e

Hash scope: artifact_sha256 describes one retrieval (2026-10-11T21:49:59Z). medRxiv regenerates this PDF: a reviewer download on 2026-10-12 had 2,761,577 bytes, SHA-256 3d37b32e8ff782201ed8ee6677a01808d4f8c86eea70350a530dde7306cab7c9 and PDF CreationDate 2026-10-11T20:08:12-07:00. The reviewer's copy's text layer matched every extracted value. The licence does not allow archiving.

Inspected artifact

Artifact SHA-256
369746bfe0117866d294e01f49c6ffbfc2d177e347872030d6233e2e7366961e
Source metadata
An Evaluation of DMR-Informed Fine-Tuning of Tissue Array-Pretrained CpGPT for Gastrointestinal Cancer Classification Using cfDNA Targeted Methylation

Original source ↗

No field-specific location recorded

Version: medRxiv version 1, posted 2026-07-29
Retrieved: 2026-10-11T21:49:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_sha256

Source artifact SHA-256: 369746bfe0117866d294e01f49c6ffbfc2d177e347872030d6233e2e7366961e

Hash scope: artifact_sha256 describes one retrieval (2026-10-11T21:49:59Z). medRxiv regenerates this PDF: a reviewer download on 2026-10-12 had 2,761,577 bytes, SHA-256 3d37b32e8ff782201ed8ee6677a01808d4f8c86eea70350a530dde7306cab7c9 and PDF CreationDate 2026-10-11T20:08:12-07:00. The reviewer's copy's text layer matched every extracted value. The licence does not allow archiving.

Inspected artifact

Artifact url
https://www.medrxiv.org/content/10.64898/2026.07.26.26358979v1.full.pdf
Source metadata
An Evaluation of DMR-Informed Fine-Tuning of Tissue Array-Pretrained CpGPT for Gastrointestinal Cancer Classification Using cfDNA Targeted Methylation

Original source ↗

No field-specific location recorded

Version: medRxiv version 1, posted 2026-07-29
Retrieved: 2026-10-11T21:49:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_url

Source artifact SHA-256: 369746bfe0117866d294e01f49c6ffbfc2d177e347872030d6233e2e7366961e

Hash scope: artifact_sha256 describes one retrieval (2026-10-11T21:49:59Z). medRxiv regenerates this PDF: a reviewer download on 2026-10-12 had 2,761,577 bytes, SHA-256 3d37b32e8ff782201ed8ee6677a01808d4f8c86eea70350a530dde7306cab7c9 and PDF CreationDate 2026-10-11T20:08:12-07:00. The reviewer's copy's text layer matched every extracted value. The licence does not allow archiving.

Inspected artifact

Doi
10.64898/2026.07.26.26358979
Source metadata
An Evaluation of DMR-Informed Fine-Tuning of Tissue Array-Pretrained CpGPT for Gastrointestinal Cancer Classification Using cfDNA Targeted Methylation

Original source ↗

No field-specific location recorded

Version: medRxiv version 1, posted 2026-07-29
Retrieved: 2026-10-11T21:49:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.doi

Source artifact SHA-256: 369746bfe0117866d294e01f49c6ffbfc2d177e347872030d6233e2e7366961e

Hash scope: artifact_sha256 describes one retrieval (2026-10-11T21:49:59Z). medRxiv regenerates this PDF: a reviewer download on 2026-10-12 had 2,761,577 bytes, SHA-256 3d37b32e8ff782201ed8ee6677a01808d4f8c86eea70350a530dde7306cab7c9 and PDF CreationDate 2026-10-11T20:08:12-07:00. The reviewer's copy's text layer matched every extracted value. The licence does not allow archiving.

Inspected artifact

Extraction method
pdftotext -layout (poppler 26.08.0) text layer, parsed by extract/extract_cpgpt2026.py
Source metadata
An Evaluation of DMR-Informed Fine-Tuning of Tissue Array-Pretrained CpGPT for Gastrointestinal Cancer Classification Using cfDNA Targeted Methylation

Original source ↗

No field-specific location recorded

Version: medRxiv version 1, posted 2026-07-29
Retrieved: 2026-10-11T21:49:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.extraction_method

Source artifact SHA-256: 369746bfe0117866d294e01f49c6ffbfc2d177e347872030d6233e2e7366961e

Hash scope: artifact_sha256 describes one retrieval (2026-10-11T21:49:59Z). medRxiv regenerates this PDF: a reviewer download on 2026-10-12 had 2,761,577 bytes, SHA-256 3d37b32e8ff782201ed8ee6677a01808d4f8c86eea70350a530dde7306cab7c9 and PDF CreationDate 2026-10-11T20:08:12-07:00. The reviewer's copy's text layer matched every extracted value. The licence does not allow archiving.

Inspected artifact

Hash scope
artifact_sha256 describes one retrieval (2026-10-11T21:49:59Z). medRxiv regenerates this PDF: a reviewer download on 2026-10-12 had 2,761,577 bytes, SHA-256 3d37b32e8ff782201ed8ee6677a01808d4f8c86eea70350a530dde7306cab7c9 and PDF CreationDate 2026-10-11T20:08:12-07:00. The reviewer's copy's text layer matched every extracted value. The licence does not allow archiving.
Source metadata
An Evaluation of DMR-Informed Fine-Tuning of Tissue Array-Pretrained CpGPT for Gastrointestinal Cancer Classification Using cfDNA Targeted Methylation

Original source ↗

No field-specific location recorded

Version: medRxiv version 1, posted 2026-07-29
Retrieved: 2026-10-11T21:49:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.hash_scope

Source artifact SHA-256: 369746bfe0117866d294e01f49c6ffbfc2d177e347872030d6233e2e7366961e

Hash scope: artifact_sha256 describes one retrieval (2026-10-11T21:49:59Z). medRxiv regenerates this PDF: a reviewer download on 2026-10-12 had 2,761,577 bytes, SHA-256 3d37b32e8ff782201ed8ee6677a01808d4f8c86eea70350a530dde7306cab7c9 and PDF CreationDate 2026-10-11T20:08:12-07:00. The reviewer's copy's text layer matched every extracted value. The licence does not allow archiving.

Inspected artifact

Licence
All rights reserved; no reuse without permission (medRxiv display licence)
Source metadata
An Evaluation of DMR-Informed Fine-Tuning of Tissue Array-Pretrained CpGPT for Gastrointestinal Cancer Classification Using cfDNA Targeted Methylation

Original source ↗

No field-specific location recorded

Version: medRxiv version 1, posted 2026-07-29
Retrieved: 2026-10-11T21:49:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.licence

Source artifact SHA-256: 369746bfe0117866d294e01f49c6ffbfc2d177e347872030d6233e2e7366961e

Hash scope: artifact_sha256 describes one retrieval (2026-10-11T21:49:59Z). medRxiv regenerates this PDF: a reviewer download on 2026-10-12 had 2,761,577 bytes, SHA-256 3d37b32e8ff782201ed8ee6677a01808d4f8c86eea70350a530dde7306cab7c9 and PDF CreationDate 2026-10-11T20:08:12-07:00. The reviewer's copy's text layer matched every extracted value. The licence does not allow archiving.

Inspected artifact

Media type
application/pdf
Source metadata
An Evaluation of DMR-Informed Fine-Tuning of Tissue Array-Pretrained CpGPT for Gastrointestinal Cancer Classification Using cfDNA Targeted Methylation

Original source ↗

No field-specific location recorded

Version: medRxiv version 1, posted 2026-07-29
Retrieved: 2026-10-11T21:49:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.media_type

Source artifact SHA-256: 369746bfe0117866d294e01f49c6ffbfc2d177e347872030d6233e2e7366961e

Hash scope: artifact_sha256 describes one retrieval (2026-10-11T21:49:59Z). medRxiv regenerates this PDF: a reviewer download on 2026-10-12 had 2,761,577 bytes, SHA-256 3d37b32e8ff782201ed8ee6677a01808d4f8c86eea70350a530dde7306cab7c9 and PDF CreationDate 2026-10-11T20:08:12-07:00. The reviewer's copy's text layer matched every extracted value. The licence does not allow archiving.

Inspected artifact

Publication status
preprint
Source metadata
An Evaluation of DMR-Informed Fine-Tuning of Tissue Array-Pretrained CpGPT for Gastrointestinal Cancer Classification Using cfDNA Targeted Methylation

Original source ↗

No field-specific location recorded

Version: medRxiv version 1, posted 2026-07-29
Retrieved: 2026-10-11T21:49:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.publication_status

Source artifact SHA-256: 369746bfe0117866d294e01f49c6ffbfc2d177e347872030d6233e2e7366961e

Hash scope: artifact_sha256 describes one retrieval (2026-10-11T21:49:59Z). medRxiv regenerates this PDF: a reviewer download on 2026-10-12 had 2,761,577 bytes, SHA-256 3d37b32e8ff782201ed8ee6677a01808d4f8c86eea70350a530dde7306cab7c9 and PDF CreationDate 2026-10-11T20:08:12-07:00. The reviewer's copy's text layer matched every extracted value. The licence does not allow archiving.

Inspected artifact

Retrieved at
2026-10-11T21:49:59Z
Source metadata
An Evaluation of DMR-Informed Fine-Tuning of Tissue Array-Pretrained CpGPT for Gastrointestinal Cancer Classification Using cfDNA Targeted Methylation

Original source ↗

No field-specific location recorded

Version: medRxiv version 1, posted 2026-07-29
Retrieved: 2026-10-11T21:49:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.retrieved_at

Source artifact SHA-256: 369746bfe0117866d294e01f49c6ffbfc2d177e347872030d6233e2e7366961e

Hash scope: artifact_sha256 describes one retrieval (2026-10-11T21:49:59Z). medRxiv regenerates this PDF: a reviewer download on 2026-10-12 had 2,761,577 bytes, SHA-256 3d37b32e8ff782201ed8ee6677a01808d4f8c86eea70350a530dde7306cab7c9 and PDF CreationDate 2026-10-11T20:08:12-07:00. The reviewer's copy's text layer matched every extracted value. The licence does not allow archiving.

Inspected artifact

How to read the evidence

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

Primary source retrieved and hashed for the 2026-10-11 plasma ctDNA literature pass.

Release history

No supporting source is linked yet.

Read original source

Download this release (gzip)
Technical metadata and extraction receipts

Stable ID: ctdnalit-20261011-cpgpt2026-source-preprint

areas
dna-genomes
contexts
clinical_research
url
https://doi.org/10.64898/2026.07.26.26358979
artifact url
https://www.medrxiv.org/content/10.64898/2026.07.26.26358979v1.full.pdf
version
medRxiv version 1, posted 2026-07-29
retrieved at
2026-10-11T21:49:59Z
artifact sha256
369746bfe0117866d294e01f49c6ffbfc2d177e347872030d6233e2e7366961e
doi
10.64898/2026.07.26.26358979
publication status
preprint
licence
All rights reserved; no reuse without permission (medRxiv display licence)
media type
application/pdf
source locator
Full artifact bytes; per-record locators on each record
archive note
Not archived: no reuse licence. The artifact_sha256 pins the bytes that were read.
hash scope
artifact_sha256 describes one retrieval (2026-10-11T21:49:59Z). medRxiv regenerates this PDF: a reviewer download on 2026-10-12 had 2,761,577 bytes, SHA-256 3d37b32e8ff782201ed8ee6677a01808d4f8c86eea70350a530dde7306cab7c9 and PDF CreationDate 2026-10-11T20:08:12-07:00. The reviewer's copy's text layer matched every extracted value. The licence does not allow archiving.
extraction method
pdftotext -layout (poppler 26.08.0) text layer, parsed by extract/extract_cpgpt2026.py
scope note
Two authors (University of Southern California; MicroTrace BioAI, Inc.) who did not develop CpGPT. They fine-tuned the published CpGPT Cancer-100M checkpoint and built the classical baselines themselves. Not peer reviewed.
Related records

    Suggest a correction